153 related articles for article (PubMed ID: 2444361)
1. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared.
Chan DW; Bruzek DJ; Oesterling JE; Rock RC; Walsh PC
Clin Chem; 1987 Oct; 33(10):1916-20. PubMed ID: 2444361
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.
Rock RC; Chan DW; Bruzek D; Waldron C; Oesterling J; Walsh P
Clin Chem; 1987 Dec; 33(12):2257-61. PubMed ID: 2446807
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
[TBL] [Abstract][Full Text] [Related]
8. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.
Finlay JA; Evans CL; Day JR; Payne JK; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Wolfert RL; Rittenhouse HG
Urology; 1998 May; 51(5):804-9. PubMed ID: 9610595
[TBL] [Abstract][Full Text] [Related]
9. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
[TBL] [Abstract][Full Text] [Related]
10. Ultrasensitive radioimmunoassay of prostate-specific antigen.
Graves HC; Wehner N; Stamey TA
Clin Chem; 1992 May; 38(5):735-42. PubMed ID: 1374691
[TBL] [Abstract][Full Text] [Related]
11. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
12. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
13. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
[TBL] [Abstract][Full Text] [Related]
14. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.
Stenman UH; Leinonen J; Alfthan H; Rannikko S; Tuhkanen K; Alfthan O
Cancer Res; 1991 Jan; 51(1):222-6. PubMed ID: 1703033
[TBL] [Abstract][Full Text] [Related]
15. Determination of prostate-specific antigen in serum by immunoradiometric assay.
Lindstedt G; Jacobsson A; Lundberg PA; Hedelin H; Pettersson S; Unsgaard B
Clin Chem; 1990 Jan; 36(1):53-8. PubMed ID: 1688745
[TBL] [Abstract][Full Text] [Related]
16. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
Zhang Y; Zippe CD; Van Lente F; Klein EA; Gupta MK
Clin Cancer Res; 1997 Jul; 3(7):1215-20. PubMed ID: 9815802
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
18. Medically significant concentrations of prostate-specific antigen in serum assessed.
Bernstein LH; Rudolph RA; Pinto MM; Viner N; Zuckerman H
Clin Chem; 1990 Mar; 36(3):515-8. PubMed ID: 1690092
[TBL] [Abstract][Full Text] [Related]
19. Time-resolved immunofluorometric assay of human prostate-specific antigen.
Vihko P; Kurkela R; Ramberg J; Pelkonen I; Vihko R
Clin Chem; 1990 Jan; 36(1):92-5. PubMed ID: 1688748
[TBL] [Abstract][Full Text] [Related]
20. New ultrasensitive assay development by using monoclonal antibodies for detecting prostate-specific antigen.
Di Silverio F; D'Eramo G; Flammia GP; Caponera M; Macrí D; Loreto A; Sciarra A
Eur Urol; 1992; 21 Suppl 1():79-82. PubMed ID: 1385136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
